Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LAWRENCE E GARBO

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1740276484
CMS profile
350947
Location
ALBANY, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$62.51

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $50.59 2
Education $11.92 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Gilead Sciences, Inc. $37.51 2
Incyte Corporation $25.00 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LAWRENCE E GARBO

NPI 1740276484 · CMS profile ID 350947

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ALBANY, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740276484?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LAWRENCE E GARBO, NPI 1740276484, CMS profile ID 350947. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740276484?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). LAWRENCE E GARBO, NPI 1740276484, CMS profile ID 350947. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740276484?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
LAWRENCE E GARBO, NPI 1740276484, CMS profile ID 350947, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1740276484?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $62.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $25.0010/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835519623 CMS
Gilead Sciences, Inc. $11.9206/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845873209 CMS
Gilead Sciences, Inc. $25.5905/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848197793 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $259.57 3
PY2020 $15.32 1
PY2021 $62.51 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021
Generated from
OP_DTL_GNRL_PGYR2021_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $54,555.31 21
PY2024 Principal investigator $121,551.17 52
PY2023 Principal investigator $130,237.17 26
PY2022 Principal investigator $53,938.23 20
PY2021 Principal investigator $175,090.52 37
PY2020 Principal investigator $226,774.25 81
PY2019 Principal investigator $398,858.14 215

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

215 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $12,027.00 12/23/2019 Non-covered Recipient Entity
Us Oncology Research Llc
Single arm study with Regorafenib and Nivolumab in MSS CRC No dispute reported 06/30/2026 629166689
Principal investigator 1 Eisai Inc. $1,375.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516309
Principal investigator 1 Eisai Inc. $11.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516311
Principal investigator 1 Eisai Inc. $43.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516315
Principal investigator 1 Eisai Inc. $175.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516317
Principal investigator 1 Eisai Inc. $300.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516319
Principal investigator 1 Eisai Inc. $175.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516321
Principal investigator 1 Eisai Inc. $175.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516323
Principal investigator 1 Eisai Inc. $1,088.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516325
Principal investigator 1 Eisai Inc. $952.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516327
Principal investigator 1 Eisai Inc. $952.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516329
Principal investigator 1 Eisai Inc. $1,088.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516331
Principal investigator 1 Eisai Inc. $11.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516333
Principal investigator 1 Eisai Inc. $36.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516335
Principal investigator 1 Eisai Inc. $36.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516337
Principal investigator 1 Eisai Inc. $1,498.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516339
Principal investigator 1 Eisai Inc. $11.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516341
Principal investigator 1 Eisai Inc. $43.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516343
Principal investigator 1 Eisai Inc. $1,481.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516345
Principal investigator 1 Eisai Inc. $1,481.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516353
Principal investigator 1 Genentech, Inc. $11,647.00 12/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
TECENTRIQ ONCOLOGY EXTENSION STUDY No dispute reported 06/30/2026 681103863
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $8,500.00 12/05/2019 Non-covered Recipient Entity
Us Oncology Research Llc
Single arm study with Regorafenib and Nivolumab in MSS CRC No dispute reported 06/30/2026 629163715
Principal investigator 1 Eisai Inc. $1,020.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516271
Principal investigator 1 Eisai Inc. $1,020.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516273
Principal investigator 1 Eisai Inc. $952.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516275
Principal investigator 1 Eisai Inc. $1,020.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516277
Principal investigator 1 Eisai Inc. $1,088.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516279
Principal investigator 1 Eisai Inc. $259.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516281
Principal investigator 1 Eisai Inc. $194.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516283
Principal investigator 1 Eisai Inc. $1,358.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516285
Principal investigator 1 Eisai Inc. $11.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516287
Principal investigator 1 Eisai Inc. $300.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516289
Principal investigator 1 Eisai Inc. $1,481.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516291
Principal investigator 1 Eisai Inc. $175.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516293
Principal investigator 1 Eisai Inc. $1,020.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516295
Principal investigator 1 Eisai Inc. $300.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516297
Principal investigator 1 Eisai Inc. $13.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516299
Principal investigator 1 Eisai Inc. $11.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516301
Principal investigator 1 Eisai Inc. $175.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516303
Principal investigator 1 Eisai Inc. $1,481.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516305
Principal investigator 1 Eisai Inc. $175.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516307
Principal investigator 1 Eisai Inc. $1,498.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516313
Principal investigator 1 Eisai Inc. $1,481.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516347
Principal investigator 1 Eli Lilly and Company $6,800.00 11/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY PC
A PHASE 1B STUDY OF AURORA A KINASE INHIBITOR LY3295668 ERBUMINE IN MONOTHERAPY AND COMBINATION THERAPY IN PATIENTS WITH METASTATIC BREAST CANCER POST CDK4/6 INHIBITOR AND ENDOCRINE THERAPY No dispute reported 06/30/2026 654292265
Principal investigator 1 Genentech, Inc. $1,250.00 11/04/2019 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
TECENTRIQ ONCOLOGY EXTENSION STUDY No dispute reported 06/30/2026 681097341
Principal investigator 1 Genentech, Inc. $5,112.00 10/24/2019 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
TECENTRIQ ONCOLOGY EXTENSION STUDY No dispute reported 06/30/2026 681095383
Principal investigator 1 Eisai Inc. $1,321.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516215
Principal investigator 1 Eisai Inc. $991.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516217
Principal investigator 1 Eisai Inc. $1,150.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516219
Principal investigator 1 Eisai Inc. $175.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516221
Principal investigator 1 Eisai Inc. $391.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516223
Principal investigator 1 Eisai Inc. $29.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516225
Principal investigator 1 Eisai Inc. $51.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516227
Principal investigator 1 Eisai Inc. $168.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516229
Principal investigator 1 Eisai Inc. $1,392.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516231
Principal investigator 1 Eisai Inc. $1,481.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516233
Principal investigator 1 Eisai Inc. $105.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516235
Principal investigator 1 Eisai Inc. $1,481.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516253
Principal investigator 1 Eisai Inc. $175.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516255
Principal investigator 1 Eisai Inc. $1,020.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516257
Principal investigator 1 Eisai Inc. $1,700.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516259
Principal investigator 1 Eisai Inc. $1,700.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516261
Principal investigator 1 Eisai Inc. $848.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516263
Principal investigator 1 Eisai Inc. $11.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516265
Principal investigator 1 Eisai Inc. $11.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516267
Principal investigator 1 Eisai Inc. $36.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516269
Principal investigator 1 Merck Sharp & Dohme Corporation $956.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction GEJ Adenocarcinoma No dispute reported 06/30/2026 691469055
Principal investigator 1 Merck Sharp & Dohme Corporation $956.00 10/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 691473785
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,000.00 09/20/2019 Non-covered Recipient Entity
Us Oncology Res Llc
A Dose Frequency Optimization, Phase IIIBIV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mgkg or 240 mg Every 2 Weeks. No dispute reported 06/30/2026 639756059
Principal investigator 1 Eisai Inc. $1,358.00 09/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516213
Principal investigator 1 Eisai Inc. $1,481.00 09/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516245
Principal investigator 1 Eisai Inc. $1,481.00 09/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516251
Principal investigator 1 Eisai Inc. $11.00 08/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516211
Principal investigator 1 Eisai Inc. $1,481.00 08/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516237
Principal investigator 1 Eisai Inc. $175.00 08/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516239
Principal investigator 1 Eisai Inc. $1,358.00 08/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516241
Principal investigator 1 Eisai Inc. $175.00 08/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516243
Principal investigator 1 Eisai Inc. $1,481.00 08/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516247
Principal investigator 1 Eisai Inc. $1,481.00 08/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516249
Principal investigator 1 Genentech, Inc. $1,250.00 08/01/2019 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
TECENTRIQ ONCOLOGY EXTENSION STUDY No dispute reported 06/30/2026 681067977
Principal investigator 1 Eisai Inc. $1,481.00 07/17/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516173
Principal investigator 1 Eisai Inc. $952.00 07/17/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516175
Principal investigator 1 Eisai Inc. $1,088.00 07/17/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516177
Principal investigator 1 Eisai Inc. $1,020.00 07/17/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516179
Principal investigator 1 Eisai Inc. $1,020.00 07/17/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516181
Principal investigator 1 Eisai Inc. $1,020.00 07/17/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516183
Principal investigator 1 Eisai Inc. $952.00 07/17/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516185
Principal investigator 1 Eisai Inc. $1,088.00 07/17/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516187
Principal investigator 1 Eisai Inc. $1,481.00 07/17/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516189
Principal investigator 1 Eisai Inc. $175.00 07/17/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516191
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 07/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 691351151
Principal investigator 1 Merck Sharp & Dohme Corporation $956.00 07/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction GEJ Adenocarcinoma No dispute reported 06/30/2026 691352904
Principal investigator 1 Merck Sharp & Dohme Corporation $956.00 07/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 691352911
Principal investigator 1 Genentech, Inc. $6,921.00 07/12/2019 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
TECENTRIQ ONCOLOGY EXTENSION STUDY No dispute reported 06/30/2026 681099397
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,331.47 06/26/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma No dispute reported 06/30/2026 686170359
Principal investigator 1 Eisai Inc. $1,481.00 06/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516169
Principal investigator 1 Eisai Inc. $1,358.00 06/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516171
Principal investigator 1 Genentech, Inc. $16,049.00 06/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
TECENTRIQ ONCOLOGY EXTENSION STUDY No dispute reported 06/30/2026 681094445
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 06/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 691300391
Principal investigator 1 Seattle Genetics, Inc. $275.00 06/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678825095
Principal investigator 1 Seattle Genetics, Inc. $275.00 06/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678825097
Principal investigator 1 Seattle Genetics, Inc. $275.00 06/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678825099
Principal investigator 1 Seattle Genetics, Inc. $275.00 06/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678825101
Principal investigator 1 AbbVie, Inc. $4,233.00 06/14/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576821
Principal investigator 1 AbbVie, Inc. $1,650.00 05/24/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576793
Principal investigator 1 AbbVie, Inc. $4,904.12 05/22/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576783
Principal investigator 1 AbbVie, Inc. $145.82 05/22/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576785
Principal investigator 1 AbbVie, Inc. $6,585.00 05/22/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576787
Principal investigator 1 AbbVie, Inc. $4,233.00 05/22/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576789
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,240.00 05/22/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma No dispute reported 06/30/2026 686170357
Principal investigator 1 AbbVie, Inc. $2,352.00 05/17/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576791
Principal investigator 1 AbbVie, Inc. $299.00 05/16/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576795
Principal investigator 1 AbbVie, Inc. $660.00 05/16/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576799
Principal investigator 1 Eisai Inc. $1,020.00 05/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516097
Principal investigator 1 Eisai Inc. $1,700.00 05/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516099
Principal investigator 1 Eisai Inc. $1,700.00 05/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516101
Principal investigator 1 Eisai Inc. $1,358.00 05/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516193
Principal investigator 1 Eisai Inc. $1,700.00 05/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516195
Principal investigator 1 Eisai Inc. $1,020.00 05/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516197
Principal investigator 1 Eisai Inc. $1,700.00 05/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516199
Principal investigator 1 Eisai Inc. $1,700.00 05/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516201
Principal investigator 1 Eisai Inc. $1,481.00 05/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516203
Principal investigator 1 Eisai Inc. $1,358.00 05/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516205
Principal investigator 1 Eisai Inc. $1,481.00 05/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516207
Principal investigator 1 Eisai Inc. $175.00 05/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516209
Principal investigator 1 Merck Sharp & Dohme Corporation $225.00 05/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction GEJ Adenocarcinoma No dispute reported 06/30/2026 691300393
Principal investigator 1 AbbVie, Inc. $1,125.00 05/10/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576797
Principal investigator 1 AbbVie, Inc. $4,958.42 05/10/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576801
Principal investigator 1 AbbVie, Inc. $235.00 05/10/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576803
Principal investigator 1 AbbVie, Inc. $150.00 05/10/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576807
Principal investigator 1 AbbVie, Inc. $500.00 05/10/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576809
Principal investigator 1 AbbVie, Inc. $838.00 05/10/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576811
Principal investigator 1 AbbVie, Inc. $192.00 05/10/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576813
Principal investigator 1 AbbVie, Inc. $274.00 05/08/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576805
Principal investigator 1 AbbVie, Inc. $2,352.00 05/08/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576815
Principal investigator 1 AbbVie, Inc. $2,475.48 05/08/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576817
Principal investigator 1 AbbVie, Inc. $1,125.00 05/08/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576819
Principal investigator 1 Genentech, Inc. $12,120.00 05/02/2019 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
TECENTRIQ ONCOLOGY EXTENSION STUDY No dispute reported 06/30/2026 681092367
Principal investigator 1 Genentech, Inc. $1,250.00 04/27/2019 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
TECENTRIQ ONCOLOGY EXTENSION STUDY No dispute reported 06/30/2026 681081331
Principal investigator 1 Eisai Inc. $175.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516103
Principal investigator 1 Eisai Inc. $300.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516121
Principal investigator 1 Eisai Inc. $300.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516123
Principal investigator 1 Eisai Inc. $1,020.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516133
Principal investigator 1 Eisai Inc. $1,020.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516135
Principal investigator 1 Eisai Inc. $1,020.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516137
Principal investigator 1 Eisai Inc. $1,009.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516147
Principal investigator 1 Eisai Inc. $175.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516149
Principal investigator 1 Eisai Inc. $29.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516151
Principal investigator 1 Eisai Inc. $51.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516153
Principal investigator 1 Eisai Inc. $1,481.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516155
Principal investigator 1 Eisai Inc. $175.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516157
Principal investigator 1 Eisai Inc. $1,358.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516159
Principal investigator 1 Eisai Inc. $1,481.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516161
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 691299795
Principal investigator 1 Merck Sharp & Dohme Corporation $956.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 691299837
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 691300134
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 691300385
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 691300387
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 691300481
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 691300485
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 691300489
Principal investigator 1 Merck Sharp & Dohme Corporation $956.00 04/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction GEJ Adenocarcinoma No dispute reported 06/30/2026 691534013
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,000.00 04/05/2019 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Dose Frequency Optimization, Phase IIIBIV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mgkg or 240 mg Every No dispute reported 06/30/2026 639756057
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $541.13 03/20/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma No dispute reported 06/30/2026 686170361
Principal investigator 1 Eisai Inc. $1,498.00 03/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516105
Principal investigator 1 Eisai Inc. $175.00 03/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516107
Principal investigator 1 Eisai Inc. $1,088.00 03/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516109
Principal investigator 1 Eisai Inc. $1,020.00 03/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516111
Principal investigator 1 Eisai Inc. $1,700.00 03/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516113
Principal investigator 1 Eisai Inc. $1,700.00 03/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516115
Principal investigator 1 Eisai Inc. $300.00 03/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516117
Principal investigator 1 Eisai Inc. $1,700.00 03/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516119
Principal investigator 1 Eisai Inc. $1,020.00 03/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516125
Principal investigator 1 Eisai Inc. $1,375.00 03/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516127
Principal investigator 1 Eisai Inc. $11.00 03/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516129
Principal investigator 1 Eisai Inc. $1,375.00 03/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516131
Principal investigator 1 Eisai Inc. $1,498.00 03/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516163
Principal investigator 1 Eisai Inc. $11.00 03/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516165
Principal investigator 1 Eisai Inc. $175.00 03/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516167
Principal investigator 1 Eisai Inc. $11.00 03/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516349
Principal investigator 1 Eisai Inc. $1,700.00 03/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516351
Principal investigator 1 Genentech, Inc. $4,083.30 02/25/2019 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
GDC0032 PH I II SOLID TUMORS AND BREAST CANCER No dispute reported 06/30/2026 681087969
Principal investigator 1 Eisai Inc. $1,375.00 02/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516059
Principal investigator 1 Eisai Inc. $1,375.00 02/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516061
Principal investigator 1 Eisai Inc. $11.00 02/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516063
Principal investigator 1 Eisai Inc. $1,498.00 02/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516065
Principal investigator 1 Eisai Inc. $11.00 02/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516067
Principal investigator 1 Eisai Inc. $175.00 02/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516069
Principal investigator 1 Eisai Inc. $1,498.00 02/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516071
Principal investigator 1 Eisai Inc. $175.00 02/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516073
Principal investigator 1 Eisai Inc. $11.00 02/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516075
Principal investigator 1 Eisai Inc. $1,358.00 02/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516077
Principal investigator 1 Eisai Inc. $11.00 02/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516079
Principal investigator 1 Eisai Inc. $175.00 02/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516139
Principal investigator 1 Eisai Inc. $1,481.00 02/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516141
Principal investigator 1 Eisai Inc. $1,358.00 02/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516143
Principal investigator 1 Eisai Inc. $11.00 02/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516145
Principal investigator 1 Merck Sharp & Dohme Corporation $225.00 02/15/2019 Non-covered Recipient Entity
ARIZONA ONCOLOGY ASSOCIATES, P.C.
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction GEJ Adenocarcinoma No dispute reported 06/30/2026 691285085
Principal investigator 1 Genentech, Inc. $10,108.00 02/05/2019 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
TECENTRIQ ONCOLOGY EXTENSION STUDY No dispute reported 06/30/2026 681080759
Principal investigator 1 Genentech, Inc. $1,250.00 01/29/2019 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
TECENTRIQ ONCOLOGY EXTENSION STUDY No dispute reported 06/30/2026 681082861
Principal investigator 1 AbbVie, Inc. $103.00 01/16/2019 Non-covered Recipient Entity
US Oncology Research LLC
M16-296 No dispute reported 06/30/2026 647576781
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $50,186.70 01/16/2019 Non-covered Recipient Entity
Us Oncology Res Llc
An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies CheckMate 627 No dispute reported 06/30/2026 639756065
Principal investigator 1 Celgene Corporation $12,138.00 01/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
Celgene - Connect MM No dispute reported 06/30/2026 675418117
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,550.00 01/15/2019 Non-covered Recipient Entity
New York Oncology Hematology, Pc
Nivo Dose Frequency Optimization Lung Trial No dispute reported 06/30/2026 639756061
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $51,751.70 01/15/2019 Non-covered Recipient Entity
New York Oncology Hematology, Pc
Adaptive Pan Malignancy Study for indications in which there is no approved immunomodulating therapy or BMS registration pathway No dispute reported 06/30/2026 639756063
Principal investigator 1 Eisai Inc. $952.00 01/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516081
Principal investigator 1 Eisai Inc. $1,020.00 01/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516083
Principal investigator 1 Eisai Inc. $1,088.00 01/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516085
Principal investigator 1 Eisai Inc. $175.00 01/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516087
Principal investigator 1 Eisai Inc. $29.00 01/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516089
Principal investigator 1 Eisai Inc. $51.00 01/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516091
Principal investigator 1 Eisai Inc. $848.00 01/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516093
Principal investigator 1 Eisai Inc. $1,392.00 01/15/2019 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702516095
Principal investigator 1 Merck Sharp & Dohme Corporation $956.00 01/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction GEJ Adenocarcinoma No dispute reported 06/30/2026 691292741
Principal investigator 1 Merck Sharp & Dohme Corporation $956.00 01/15/2019 Non-covered Recipient Entity
SANTA BARBARA HEMATOLOGY ONCOLOGY MEDICAL GROUP, INC.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 691294831